HCM
HUTCHMED (China) Limited
There isn't enough reported data to score HCM yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
HCM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Strong |
HCM's profitability and balance sheet are currently strong. There isn't enough data to rate its revenue and cash flow.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
HCM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.1x | $2.63 | -82% |
| Current | 5.7x | $14.85 | — |
| Fair | 5.8x | $3.00 | -80% |
| Expensive | 67x | $34.83 | +135% |
Historical ranges are pointers, not guarantees.
HCM's PE is 5.7x, but its earnings don't support one, so it isn't a reliable read right now.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over HCM in the historical PE scenario, which offers more potential upside but is not a forecast.
HCM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect HCM's losses to grow, with revenue growing.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
HCM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.52 | +1200% |
| Q2 2025 | $0.53 | +$0.57 |
| Q4 2024 | $0.04 | -67% |
| Q2 2024 | -$0.04 | +$0.01 |
| Q4 2023 | $0.12 | +$0.55 |
| Q2 2023 | -$0.05 | +$0.25 |
| Q4 2022 | -$0.43 | -$0.18 |
| Q2 2022 | -$0.30 | -$0.05 |
HCM has the edge over UNH in the latest year-over-year earnings comparison.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
HCM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $270.8M | -17% |
| Q2 2025 | $277.7M | -9.2% |
| Q4 2024 | $324.5M | +6.4% |
| Q2 2024 | $305.7M | -43% |
| Q4 2023 | $305.1M | +36% |
| Q2 2023 | $532.9M | +164% |
| Q4 2022 | $224.4M | +13% |
| Q2 2022 | $202M | +28% |
HCM's revenue has slid since its 2023 peak: $271M last quarter, down 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -13% | +17 points |
| Q2 2025 | -1.3% | -22 points |
| Q4 2024 | -5% | +89 points |
| Q2 2024 | -9% | +88 points |
| Q4 2023 | -31% | +62 points |
| Q2 2023 | 21% | +112 points |
| Q4 2022 | -94% | +3.8 points |
| Q2 2022 | -97% | -24 points |
HCM's operating margin was −13% last quarter, up 17 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over HCM in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
HCM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $3.4M | -90% |
| Q2 2025 | -$82.2M | -$32.2M |
| Q4 2024 | $32.5M | +$47.9M |
| Q2 2024 | -$49.9M | -125% |
| Q4 2023 | -$15.4M | +$184.3M |
| Q2 2023 | $202M | +$307.7M |
| Q4 2022 | -$199.7M | -$59.3M |
| Q2 2022 | -$105.6M | -$25.4M |
HCM has burned cash in most quarters: −$96M over the past year, against −$119M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
HCM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +327K shares |
| 1 year | +0.4% | +3.7M shares |
| 3 years | +31% | +207M shares |
| 5 years | +46% | +273M shares |
HCM has 873M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | $36.1M |
| Q4 2023 | — |
| Q2 2023 | $9.1M |
| Q4 2022 | — |
| Q2 2022 | $48.1M |
| Q4 2021 | $551,000 |
| Q2 2021 | $26.8M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over HCM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
HCM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -6.5x | Net Cash |
HCM has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
HCM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 79.2 | Neutral |
HCM's weekly RSI is 59 (neutral) and its Stochastic is 79 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
HCM PE vs Healthcare Sector
| Metric | HCM | Sector median | Relative |
|---|---|---|---|
| PE | 5.7x | 26x | 78% below |
| PE % | 46 | 29 | 17 pts above |
HCM has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
HCM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.2 | 4.4% above |
| 20 week MA | $13.0 | 14% above |
| 50 week MA | $13.4 | 11% above |
| 100 week MA | $14.3 | 4% above |
| 200 week MA | $15.4 | 3.8% below |
HCM has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 3.8% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
HCM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.5 | $29.5 | +16% |
| 2021 | $29.5 | $35.3 | +20% |
| 2022 | $35.3 | $14.0 | -60% |
| 2023 | $14.0 | $18.1 | +29% |
| 2024 | $18.1 | $14.3 | -21% |
| 2025 | $14.3 | $13.8 | -3.5% |
| 2026 YTD | $13.8 | $14.9 | +7.8% |
HCM has finished lower in three of the last six years. It's up 7.8% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over HCM on returns for 2026, with the stronger performance.